FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a novel crystalline form of a compound of formula 
, which possesses higher solubility in water and storage stability. The novel crystalline form II of formula (A) compound is characterised by the presence of a profile of powder X-ray diffraction with the following peaks ±0.20° (2 theta): 5.10; 10.07; 14.90; 15.15; 15.67; 17.24; 17.84; 18.51; 19.23; 20.25; 20.37; 22.01; 22.63; 23.12; 24.76; 25.40; 27.78; 28.97; 31.02. The invention also relates to a method of obtaining the formula (A) compound in the crystalline form II and solid pharmaceutical compositions, containing the said crystalline form.
EFFECT: obtaining the novel n crystalline form of the compound.
11 cl, 2 tbl, 5 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL CRYSTALLINE FORMS OF SODIUM SALT OF (4-{4-[5-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLAMINO)PYRIDIN-2-YL]PHENYL}CYCLOHEXYL) ACETIC ACID | 2011 |
|
RU2612556C2 |
| METHOD OF PRODUCING N-[5-(3,5-DIFTORBENZIL)-1H-INDAZOLE-3-YL]-4-(4-METHYLPIPERAZINE-1-YL)-2-(TETRAHYDROPYRAN-4-YLAMINO)BENZAMIDE | 2013 |
|
RU2602071C2 |
| SALTS OF DASATINIB IN AMORPHOUS FORM | 2014 |
|
RU2655435C2 |
| DASATINIB SALTS IN CRYSTALLINE FORM | 2014 |
|
RU2662805C2 |
| FORM IV OF IVABRADINE HYDROCHLORIDE | 2012 |
|
RU2619121C2 |
| AMORPHOUS FORM OF THIOCOLCHICINE COMPOUND | 2015 |
|
RU2684925C2 |
| METHOD OF MODIFYING CRYSTALLISATION PROCESS OF MEDICINAL SUBSTANCE | 2004 |
|
RU2388757C2 |
| S-CRYSTAL FORM OF IVABRADINE HYDROCHLORIDE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | 2014 |
|
RU2658824C2 |
| POLYMORPHOUS AND AMORPHOUS FORMS OF {2-FLUORINE-5-[3-((E)-2-PYRIDINE-2-ILVINYL)-1N-INDAZOLE-6-ILAMINE]PHENYL}AMIDE 2, 5-DIMETHYL-2N-PYRAZOLE-3-CARBONIC ACID | 2005 |
|
RU2324692C1 |
| CRYSTAL FORM OF PARP-1 INHIBITOR AND ITS PRODUCTION METHOD | 2018 |
|
RU2792620C2 |
